Atlas Trials

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Clinical trial NCT05255484 · TERMINATED

Trial details

NCT number
NCT05255484
Sponsor
LaNova Medicines Limited
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Solid Tumor
Start date
2022-05-26
Primary completion
2023-10-06
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.